Mingchen Yu
Impact in
-
- Cancer, Hypoxia, and Metabolism
-
- Glioma Diagnosis and Treatment
Papers in
-
- Peroxisome Proliferator-Activated Receptors 2
-
- Immunotherapy and Immune Responses 3
- Immune Cell Function and Interaction 2
- Immune cells in cancer 2
- Co-authors
- Wei Zhang (8 shared papers)You Zhai (12 shared papers)Di Wang (10 shared papers)Changqing Pan (10 shared papers)Zhongfang Shi (8 shared papers)Tao Jiang (9 shared papers)Fan Wu (6 shared papers)Ulf D. Kahlert (2 shared papers)
In The Last Decade
Mingchen Yu
23 papers receiving 478 citations
Mingchen Yu's Hit Papers
Peers
Comparison fields: 5 of 81
- Cancer Research 111
- Genetics 56
- Immunology 88
- Oncology 101
- Neurology 31
Countries citing papers authored by Mingchen Yu
This map shows the geographic impact of Mingchen Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingchen Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingchen Yu more than expected).
Fields of papers citing papers by Mingchen Yu
This network shows the impact of papers produced by Mingchen Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingchen Yu. The network helps show where Mingchen Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Mingchen Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma Hit paper breakdown → | 2024 | 130 |
| 2 | 2021 | 59 | |
| 3 | 2023 | 44 | |
| 4 | 2018 | 32 | |
| 5 | 2017 | 30 | |
| 6 | 2022 | 29 | |
| 7 | 2023 | 22 | |
| 8 | 2023 | 21 | |
| 9 | 2016 | 16 | |
| 10 | 2016 | 13 | |
| 11 | 2005 | 12 | |
| 12 | 2025 | 12 | |
| 13 | 2023 | 10 | |
| 14 | 2022 | 10 | |
| 15 | 2017 | 9 | |
| 16 | 2023 | 8 | |
| 17 | 2021 | 8 | |
| 18 | 2016 | 5 | |
| 19 | 2016 | 5 | |
| 20 | 2024 | 3 |
About Mingchen Yu
Mingchen Yu is a scholar working on Molecular Biology, Immunology, Genetics, Oncology and Pathology and Forensic Medicine, having authored 28 papers that have together received 484 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (6 papers), CAR-T cell therapy research (5 papers), Cancer, Hypoxia, and Metabolism (4 papers), Neuroinflammation and Neurodegeneration Mechanisms (3 papers), Immunotherapy and Immune Responses (3 papers), Immune Cell Function and Interaction (2 papers), Immune cells in cancer (2 papers) and Peroxisome Proliferator-Activated Receptors (2 papers). The work is most often cited by research in Cancer Research (111 citations), Genetics (56 citations), Immunology (88 citations), Oncology (101 citations) and Neurology (31 citations). Mingchen Yu has collaborated with scholars based in China, Germany and Taiwan. Frequent co-authors include Wei Zhang, You Zhai, Di Wang, Changqing Pan, Zhongfang Shi, Tao Jiang, Fan Wu, Ulf D. Kahlert, Guanzhang Li and Huimin Hu. Their work appears in journals such as Neurochemical Research, Frontiers in Immunology, Theranostics, Cancer Letters and Signal Transduction and Targeted Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.